COVID-19 is now a common disease, yet peripheral prognostic biomarkers have not been established. However, the identification of a protein signature capable of classifying COVID-19 sub-phenotypes with poor outcomes may enable the discovery of new therapeutic targets.
Using three independent COVID-19 patient cohorts and Olink® Explore 1536, Dr. Matsumoto collaborated with Massachusetts General Hospital to examine the plasma protein profiles of critical COVID-19 patients on Days 1 – 10 spanning hyperacute, acute, and subacute phases. Protein profiles between healthy controls, COVID-19 patients with early recovery, and COVID-19 with late recovery or death were compared.
A 4-protein signature (WFDC2, GDF15, CHI3L1, KRT19) was identified for predicting mortality of critical COVID-19 patients in the hyperacute phase (Day 1), with an area under the curve (AUC) of 0.852 with a sensitivity of 100% and a specificity of 66.3%. This work discovered a clinically useful biomarker signature indicative of prognosis in the hyperacute phase in critical COVID-19 patients.
The webinar covers the following points:
4 proteins were significantly upregulated on Day 1 in critical COVID-19 patients who did not survive compared to critical COVID-19 patients who did survive
Co-expression network analysis revealed an enrichment in cell adhesion and immune system process
Identification of 4 new clinical survival phenotypes.
Hisatake Matsumoto, Ph.D. Assistant Professor at Osaka University